Severe Alzheimer's Disease: Treatment Effects on Function and Care Requirements

Journal of the American Medical Directors Association

Volumn 12, Issue 2, 2011, Pages 99-104

  Kerwin, Diana ^a   Claus, Thomas H ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b PPSI   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Function; Memantine

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TACRINE;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); DAILY LIFE ACTIVITY; HUMAN; LIVER TOXICITY; LONG TERM CARE; NURSING HOME; REVIEW;

EID: 78751704131     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2010.06.011     Document Type: Review

References (41)

1. Alzheimer's Association. Alzheimer's disease facts and figures 2008. Alzheimer's Association web site. Available at: Accessed March 5, 2009. http://www.alz.org/alzheimers_disease_facts_figures.asp.
2. Brookmeyer R., Gray S., Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998, 88:1337-1342.
3. Hebert L.E., Beckett L.A., Scherr P.A., Evans D.A. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord 2001, 15:169-173.
4. McDowell I. Canadian study of health and aging: Study methods and prevalence of dementia. Can Med Assoc J 1994, 150:899-913.
5. Feldman H., Woodward M. The staging and assessment of moderate to severe Alzheimer disease. Neurology 2005, 65:S10-S17.
6. Galasko D. An integrated approach to the management of Alzheimer's disease: Assessing cognition, function and behavior. Eur J Neurol 1998, 5:S9-S17.
7. Jeste D.V., Blazer D., Casey D., et al. ACNP White Paper: Update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008, 33:957-970.
8. Aguero-Torres H., Fratiglioni L., Winblad B. Natural history of Alzheimer's disease and other dementias: Review of the literature in the light of the findings from the Kungsholmen Project. Int J Geriatr Psychiatry 1998, 13:755-766.
9. Shega J.W., Ellner L., Lau D.T., Mazwell T.L. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: A survey of Hospice medical directors. J Palliative Med 2009, 12:779-783.
10. Fillit H.M., Doody R.S., Binaso K., et al. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. Am J Geriatr Pharmacother 2006, 4:S9-S24.
11. Namenda [package insert] 2007, Forest Laboratories Inc, St. Louis, MO.
12. Tariot P.N., Farlow M.R., Grossberg G.T., et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004, 291:317-324.
13. Caltagirone C., Bianchetti A., Di Luca M., et al. Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. Drugs Aging 2005, 22:1-26.
14. Geldmacher D.S., Frolich L., Doody R.S., et al. Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging 2006, 10:417-429.
15. Geldmacher D.S., Provenzano G., McRae T., et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. J Am Geriatr Soc 2003, 51:937-944.
16. Beusterien K.M., Thomas S.K., Gause D., et al. Impact of rivastigmine use on the risk of nursing home placement in a US sample. CNS Drugs 2004, 18:1143-1148.
17. Feldman H., Gauthier S., Hecker J., et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003, 51:737-744.
18. Hoe J., Katona C., Orrell M., Livingston G. Quality of life in dementia: Care recipient and caregiver perceptions of quality of life in dementia: the LASER_AD study. Int J Geriatr Pscyhiatry 2007, 22:1031-1036.
19. Smith B., Chur-Hansen A., Neale A., Symon J. Quality of life and cholinesterase inhibitors: A qualitative study of patients with Alzheimer's disease and their carers. Australas Psych 2008, 16:433-437.
20. Winblad B., Poritis N. Memantine in severe dementia: Results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999, 14:135-146.
21. Winblad B., Engedal K., Soininen H., et al. Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's disease: Results from a one-year placebo-controlled study and two-year follow-up study [abstract]. Int Psychogeriatr 2003, 15:293-294.
22. Winblad B., Kilander L., Eriksson S., et al. Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet 2006, 367:1057-1065.
23. Tariot P.N., Cummings J.L., Katz I.R., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 2001, 49:1590-1599.
24. Black S.E., Doody R., Li H., et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. Neurology 2007, 69:459-469.
25. Homma A., Imai Y., Tago H., et al. Donepezil treatment of patients with severe Alzheimer's disease in a Japanese population: Results from a 24-week, double-blind, placebo-controlled, randomized trial. Dement Geriatr Cogn Disord 2008, 25:399-407.
26. Shah S.N., Keohane D., Strunk B.D., et al. Retrospective analysis of characteristics in long-term care residents with Alzheimer's disease continuing versus discontinuing donepezil treatment [abstract]. J Am Geriatr Soc 2004, 52:S49.
27. Karaman Y., Erdogan F., Koseoglu E., et al. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005, 19:51-56.
28. Burns A., Spiegel R., Quarg P. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 2004, 19:243-249.
29. Blesa R., Davidson M., Kurz A., et al. Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months. Dement Geriatr Cogn Disord 2003, 15:79-87.
30. Wilkinson D.G., Hock C., Farlow M., et al. Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSE ≤12) for up to six months. Int J Clin Pract 2002, 56:509-514.
31. Burns A., Bernabei R., Bullock R., et al. Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): A randomised, placebo-controlled, double-blind trial. Lancet Neurol 2009, 8:39-47.
32. Reisberg B., Doody R., Stoffler A., et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003, 348:1333-1341.
33. Winblad B., Jones R.W., Wirth Y., et al. Memantine in moderate to severe Alzheimer's disease: A meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord 2007, 24:20-27.
34. Rive B., Vercelletto M., Damier F.D., et al. Memantine enhances autonomy in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2004, 19:458-464.
35. Feldman H.H., Schmitt F.A., Olin J.T. Activities of daily living in moderate-to-severe Alzheimer disease: An analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord 2006, 20:263-268.
36. Atri A., Shaughnessy L.W., Locascio J.J., Growdon J.H. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008, 22:209-221.
37. Hill J., Fillit H., Thomas S.K., Chang S. Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias. Pharmacoeconomics 2006, 24:265-280.
38. Brangman S.A. Long-term cholinesterase inhibitor therapy for Alzheimer's disease: Implications for long-term care. Am J Alzheimers Dis Other Dement 2003, 18:79-84.
39. Andersen C.K., Wittrup-Jensen K.U., Lolk A., et al. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes 2004, 2:52.
40. Pedone C., Lapane K.L., Mor V., Bernabei R. Donepezil use in US nursing homes. Aging Clin Exp Res 2004, 16:60-67.
41. Bright-Long L. Alzheimer's treatment in nursing homes: Room for improvement. J Am Med Dir Assoc 2006, 7:90-95.